Erdafitinib,Vinflunine,Docetaxel,Pembrolizumab,talazoparib,enzalutamide,Cabozantinib,Atezolizumab
Janssen,pierre fabre,Merck,pfizer,astellas,roche
['contact03', 'talapro,2', 'talapro2', 'bladder', 'gusm', 'urothelial', '#thor', 'erdafitinib', 'ts,perio,i', 'vesper', 'rcc,(-irccs),(-srcc),(-urcc)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'mibc', 'crpc', 'ts,perio,1']
day 4 #asco23 highlights 1. #talapro2: parpi + enza in mcrpc 2. #thor: erdafitinib in fgfr urothelial cancer 3. #vesper: ddmvac vs gem/cis periop mibc 4. #contact03: re-challenge io in rcc #onctwitter #medtwitter #gusm #kidneycancer #bladdercancer 1/9
Practice changing 🗣 for community oncologists: w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @WilmotCancer. Views are our own. COI: https://t.co/cJOjp0RvQE